Emkay

Research

June 01, 2007

BUY

Rs110
Target Price

Price Performance

(%)	1M	3M	6M	12M
Absolute	30	36	46	43
Rel. to Sensex	24	21	37	2

Stock Details

Sector	Financial Services
Reuters	SREI.BO
Bloomberg	SREI@IN
Equity Capital (Rs mn)	1090
Face Value	Rs10
52 Week H/L	72/31
Market Cap	Rs7.8bn/USD192mn
Daily Avg Volume (No	of shares) 410,926
Daily Avg Turnover (US	\$\$) 0.6

Shareholding Pattern (%)

(31st Mar.'07)	
Promoters	20.1
FII	43.7
Institutions	1.5
Private Corp.	13.0
Public	21.8

Kashyap Jhaveri

Kashyap.jhaveri@emkayshare.com +91 22 6612 1249

SREI Infrastructure Finance

Value unleashed

French financial services giant BNP Paribas's leasing group (BPLG) has taken 50% stake in SREI Infrastructure Finance's (SREI) equipment financing business for Rs7.8bn. Of the total consideration of Rs7.8bn, Rs3.75bn will be paid to SREI as a consideration of transferring the equipment financing business to the 50:50 JV.

The deal puts valuation of SREI's equipment financing business (100%) at Rs15.5bn, which is 2x, its current market capitalisation. Add to that the value of its subsidiaries like private equity (AUM of \$185mn, valued at Rs1.3bn), value of existing project financing business (Rs4.8bn at 1x FY07 book value) and value of the 16% stake in Quippo (Rs640mn at 1x book value), the total value of SREI comes to Rs11.6bn.

We expect significant synergies from the deal for SREI as with BPLG holding its back; it could result in significant savings in cost of funds. On its current asset base of Rs45bn, a 25bps reduction in cost of funds can add Rs120mn to the net profit. Also BLPG, being one of the largest leasing companies in Europe brings in its huge expertise in the business.

Even if one were to give 40% discount to the valuation given by BNP Paribas to the equipment financing business, SREI's valuation works out to Rs11.6bn or Rs110 per share.


We have always contended that SREI's valuations at 0.7x FY09E ABV are at significant discount to its peers and need rerating looking at the niche positioning, high market share and less risky model in the equipment financing business. The above-mentioned deal exactly signifies that. We are revising our price target on the stock to Rs110.

BNP Paribas takes 50% stake in SREI's asset financing business

BPLG has picked up 50% stake in SREI's equipment financing business for a total consideration of Rs7.8bn. Under the deal, BPLG will contribute Rs7.8bn to the net worth of the joint venture company. Of Rs7.8bn, Rs3.8bn will be paid to SREI for transferring the equipment financing business to the JV. SREI will transfer Rs45bn worth of assets and all of its liabilities to the JV. SREI will also make additional contribution of Rs250mn to the joint venture taking the total net worth of the JV to Rs8.0bn.

BPLG is subsidiary of French financial services giant, BNP Paribas. BPLG currently manages about €14bn of leasing assets and has presence in about 11 countries in the world.

Deal structure



Proforma Balance sheet of the Joint venture

Liabilities	Rs bn	Assets	Rs bn
Net worth			
SREI	0.25	Assets	44.00
BPLG	7.75	Cash	4.00
Total	8.00		
Liabilities	40.00		
Total	48.00	Total	48.00

Source: Company, Emkay Research

Emkay Research 01 June 2007 1

The structure of SREI post JV

Businesses to be retained in existing SREI	Businesses to be transferred
Project financing	Equipment financing
Private equity	Insurance broking
Merchant/investment banking	50% to be held by SREI and 50% by BPLG
ZAO SREI Leasing (Russian venture)/Quipo	

Source: Company, Emkay Research

Proforma Balance sheet of SREI post JV

Liabilities	Rs bn	Assets	Rs bn
Net worth	5.00	Investments	1.50
Liabilities	5.30	Project financing	5.30
		Cash	3.50
Total	5.00	Total	5.00

Source: Company, Emkay Research

Immense benefits for SREI

We see two benefits for SREI out of this deal, viz.,

- The Indian infrastructure story is a known fact to everyone on the street. The huge imminent infrastructure investment of \$300bn+ has put SREI in a sweet spot with 30%+ market share in the infrastructure related equipment financing market. With the above mentioned deal, SREI gets much required funding without having to dilute equity in the parent company
- 2. Supposing the deal had not happened and SREI goes for an equity dilution for funding the future growth, it will unnecessarily dilute the existing shareholders' stake in the other businesses of SREI thereby depriving them of the immense value being created in this business. For example, private equity business which is now manages assets worth \$185mn (68% growth over last year), Quipo Infrastrcutre Investments in which the company has 16% stake and which has Rs3bn of assets under management.

Valuations not expensive for BPLG if one looks at benefits

At 28.2x FY07E EPS and 2.0x book value, the valuations might look expensive and one would wonder why BPLG has paid so high for the business. However, there are lots of synergies that BPLG can derive from this JV and we believe that taking them into account, BPLG may not have paid to far for the stake.

- BPLG straight forward gets access to 40% market share in the infrastructure related equipment financing market in India it also gives BPLG an access to nearly 40+ branches and offices of SREI.
- If BPLG was to enter the Indian infrastructure financing market on its own, it would take it years to establish itself. Players like Citigroup, GE Capital and ICICI Bank still share very small portion of the market compared with 30%+ share held by SREI which itself speaks about entry barriers in this business
- 3. With BPLG being a partner in JV, we believe there can be significant savings in cost of funds for the joint venture. Even a 25bps reduction in cost of funds can add Rs120mn to the bottomline of the JV on an asset base of Rs45bn. This itself means incremental growth of 21% in the FY07E net profit.

Valuations of the deal

Taladiono of the deal	
Particulars	Rs bn
Valuation of the asset financing business (50% stake taken for Rs7.8bn	15.5
Standalone PAT of SREI of FY07E	0.6
PER (x)	28.2
P/BV (x)	2.0

Source: Company, Emkay Research

Emkay Research 01 June 2007 2

3

We see SREI's value at atleast Rs110 per share

The deal puts valuation of SREI's equipment financing business (100%) at Rs15.5bn which is 2x its current market capitalisation. Even if one were to give 40% discount to the valuation given by BPLG to the equipment financing business (given the fact that BPLG is a strategic investor), SREI's valuation works out to Rs11.6bn or Rs110 per share if one adds the value of subsidiaries and other businesses.

Particulars	Rs mn	Comments
Value of 50% stake in Joint venture	4,650	@40% discount to valuations given by BPLG
Value of the retained balance sheet excluding the subsidiary value#	4,750	@ 1x book value
Value of private equity	1,332	11x management fees of 1.5%
Value of Quipo	640	@1x book value
Total	11,622	
Per share	107	

#Excluding the investments in JV and private equity

We have always contended that SREI's valuations at 0.7x FY09E ABV are at significant discount to its peers and need rerating looking at the niche positioning, high market share and less risky model in the equipment financing business. The above-mentioned deal exactly signifies that. We are revising our price target on the stock to Rs110.

At our target price, the valuations might look stretched at 44.0x FY07E EPS and 2.2x FY07E ABV. Nevertheless, the key points to be noted here are that

- a) The current balance sheets of SREI as well as SREI are underleveraged. With Rs8bn of net worth in the JV, the assets under equipment financing can be doubled and that in the retained business can be grown 9x on the existing equity, and,
- b) The standalone SREI would have investments and cash worth Rs5bn which keep the earnings as well as ROE subdued.

At our target price of Rs110, the stock would trade at 11.7x our FY09E# EPS and 1.8x FY09E# ABV.

The numbers of FY09E are provisional, we will review them once we revise our numbers on finalization of the

DISCLAIMER: This document is not for public distribution and has been furnished to you solely for your information and may not be reproduced or redistributed to any other person. The manner of circulation and distribution of this document may be restricted by law or regulation in certain countries, including the United States. Persons into whose possession this document may come are required to inform themselves of, and to observe, such restrictions. This material is for the personal information of the authorized recipient, and we are not soliciting any action based upon it. This report is not to be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. No person associated with Emkay Share & Stock Brokers Ltd is obligated to call or initiate contact with you for the purposes of elaborating or following up on the information contained in this document. The material is based upon it, accepts any liability arising from the use of this document. The recipient of this material should not be relied upon. Neither Emkay Share & Stock Brokers Ltd, nor any person connected with it, accepts any liability arising from the use of this document. The recipient of this material should rely on their own investigations and take their own professional advice. Opinions expressed are our current opinions as of the date appearing on this material only. While we endeavor to update on a reasonable basis the information discussed in this material, there may be regulatory, compliance, or other reasons that prevent us from doing so. Prospective investors and others are cautioned that any forward-looking statements are not predictions and may be subject to change without notice. We and our affiliates, officers, directors, and employees world wide, including persons involved in the preparation or issuance of this material may; (a) from time to time, have long or short positions in, and buy or sell the securities thereof, of company (ies) m

Emkay Share and Stock Brokers Ltd.,

Paragon Center, Ground Floor, C-6

Pandurang Budhkar Marg, Worli, Mumbai – 400 013. , Tel no. 66121212. Fax: 66121299

Emkay Research 01 June 2007